| TLPH |
TALPHERA, INC. |
Common Stock, $0.001 par value |
7.9% |
$1,543,350 |
|
3,589,186 |
|
Rock Springs Capital Management LP |
10 Sep 2025 |
| ACRS |
Aclaris Therapeutics, Inc. |
Common Stock, $0.00001 par value |
4.7% |
$7,720,853 |
|
5,046,309 |
|
Rock Springs Capital Management LP |
31 Mar 2025 |
| MREO |
MEREO BIOPHARMA GROUP PLC |
Ordinary Shares, nominal value 0.003, per ordinary share |
4.2% |
$87,229,423 |
|
33,421,235 |
|
Rock Springs Capital Management LP |
31 Mar 2025 |
| TVTX |
Travere Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
3.3% |
$53,545,523 |
-$37,621,463 |
2,921,196 |
-41% |
Rock Springs Capital Management LP |
31 Mar 2025 |
| SPRB |
Spruce Biosciences, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Rock Springs Capital Management LP |
03 Jul 2025 |
| INZY |
Inozyme Pharma, Inc. |
Common stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Rock Springs Capital Management LP |
30 Jun 2025 |
| XLO |
Xilio Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Rock Springs Capital Management LP |
31 Mar 2025 |